• 検索結果がありません。

A Novel mTOR Inhibitor Anthracimycin for the Treatment of Human Hepatocellular Carcinoma

N/A
N/A
Protected

Academic year: 2021

シェア "A Novel mTOR Inhibitor Anthracimycin for the Treatment of Human Hepatocellular Carcinoma"

Copied!
2
0
0

読み込み中.... (全文を見る)

全文

(1)

A Novel mTOR Inhibitor Anthracimycin for the Treatment of Human Hepatocellular Carcinoma

著者 林 智之

著者別表示 Hayashi Tomoyuki

雑誌名 博士論文要旨Abstract 

学位授与番号 13301甲第4593号

学位名 博士(医学)

学位授与年月日 2017‑09‑26

URL http://hdl.handle.net/2297/00049647

doi: 10.21873/anticanres.11706

Creative Commons : 表示 ‑ 非営利 ‑ 改変禁止 http://creativecommons.org/licenses/by‑nc‑nd/3.0/deed.ja

(2)

参照

関連したドキュメント

Thus, the efflux transporter MRP3 was up-regulated in sorafenib-resistant clones depending on the strength of resistance, suggesting that MRP3 protein transports

HepG2 and Huh28 cells were cultured in C-82 (activated form of prodrug PRI-724) to evaluate the inhibition of CBP/β- catenin interaction, because these two cell lines

Ueshima K, Kudo M, Ikeda M, Torimura T, Tanabe N, Aikata H, Izumi N, Yamasaki T, Nojiri S, Hino K, Tsumura H, Kuzuya T, Isoda N, Yasui K, Yoshimura K, Okusaka T,

However, a previous report found no significant relationship between DNMT mRNA levels and portal vein involvement and tumor differentiation in HCCs (Saito

The number of patients treated with surgical resection, local ablation therapy and transcatheter arterial chemoembo- lization was 2, 7 and 14 in the K2-treated group,

第 2 章では,次世代インテグラーゼ阻害剤 S/GSK1349572 の in vitro

E92Q, a signature mutant observed in clinical failure of EVG (36), was also detected in an in vitro isolation of resistance study using MT-2 cells and HIV-1 IIIB (47).. Likewise, this

Title Phosphorylation of retinoid X receptor suppresses its ubiquitination in human hepatocellular carcinoma( 内容の要旨 (Summary) ) Author(s) 足立, 政治 Report No.(Doctoral